Detalles de la búsqueda
1.
Efficacy and safety of nilotinib in chronic myeloid leukaemia patients who failed to achieve a treatment-free remission period after imatinib discontinuation: Results of the French Nilo post-STIM study.
Br J Haematol;
201(6): 1116-1124, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37004981
2.
Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial.
Haematologica;
107(12): 2859-2869, 2022 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35615931
3.
Assessment of droplet digital polymerase chain reaction for measuring BCR-ABL1 in chronic myeloid leukaemia in an international interlaboratory study.
Br J Haematol;
194(1): 53-60, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34114218
4.
Budget Impact of Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia With Sustained Deep Molecular Response.
Value Health;
24(5): 683-690, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33933237
5.
Risk of molecular recurrence after tyrosine kinase inhibitor discontinuation in chronic myeloid leukaemia patients: a systematic review of literature with a meta-analysis of studies over the last ten years.
Br J Haematol;
189(3): 452-468, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32072631
6.
Novel analytical methods to interpret large sequencing data from small sample sizes.
Hum Genomics;
13(1): 41, 2019 08 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-31470908
7.
Kinetics of molecular recurrence after tyrosine kinase inhibitor cessation in chronic phase chronic myelogenous leukaemia patients.
Br J Haematol;
204(4): 1536-1539, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38323384
8.
Poor prognosis of chromosome 7 clonal aberrations in Philadelphia-negative metaphases and relevance of potential underlying myelodysplastic features in chronic myeloid leukemia.
Haematologica;
104(6): 1150-1155, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30573507
9.
Impact of second decline rate of BCR-ABL1 transcript on clinical outcome of chronic phase chronic myeloid leukemia patients on imatinib first-line.
Ann Hematol;
98(5): 1159-1168, 2019 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-30798348
10.
Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group.
Cancer;
124(14): 2956-2963, 2018 07 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-29723417
11.
Acquired glucose 6-phosphate dehydrogenase (G6PD) deficiency in a patient with Chronic Myelomonocytic Leukemia.
Br J Haematol;
197(4): e45-e48, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-34989400
12.
Onset of blast crisis in chronic myeloid leukemia patients in treatment-free remission.
Haematologica;
107(12): 2944-2949, 2022 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35924576
13.
Molecular characterization and follow-up of five CML patients with new BCR-ABL1 fusion transcripts.
Genes Chromosomes Cancer;
54(10): 595-605, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26252834
14.
A single center evaluation of cost savings related to treatment-free remission in chronic myeloid leukemia patients: the prerequisites of a pharmaco-economy larger study.
Br J Haematol;
189(3): e97-e100, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32043283
15.
ELN 2013 response status criteria: relevance for de novo imatinib chronic phase chronic myeloid leukemia patients?
Am J Hematol;
90(1): 37-41, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25293449
16.
Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy.
Haematologica;
99(3): 458-64, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-24362549
17.
European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission.
J Clin Oncol;
: JCO2301647, 2024 Mar 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-38471049
18.
Molecular monitoring of patients with ETV6-PDGFRB rearrangement: Implications for therapeutic adaptation.
Br J Haematol;
182(1): 148-152, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-28485070
19.
Quantitative phosphoproteomics revealed interplay between Syk and Lyn in the resistance to nilotinib in chronic myeloid leukemia cells.
Blood;
118(8): 2211-21, 2011 Aug 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-21730355
20.
Specific High-Sensitivity Enzymatic Reporter UnLOCKing-Mediated Detection of Oncogenic BCR::ABL1 and EGFR Rearrangements.
CRISPR J;
6(2): 140-151, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36912819